Tempus and NYU Langone Health have signed a multi-year strategic collaboration to drive precision oncology using molecular profiling and data-driven research. The Tempus-NYU Langone collaboration will enable the work of the Center for Molecular Oncology at NYU Langone Health’s Laura and Isaac Perlmutter Cancer Center, a comprehensive effort to study the biology of cancer as it evolves over time.
The collaboration is expected to drive efforts in genomic diagnostics, with the eventual goal of improving patient outcomes and helping to guide future care. The organizations have also announced the launch of a prospective observational study called “Serial Molecular Profiling and Monitoring of Human Cancer.” Patients participating in the study will undergo sequencing at various time points during treatment to generate the longitudinal datasets that will be critical to the effort.
In addition to the initial research study, other work included in the collaboration involves assay validation, biomarker identification, biological modeling, real-world data analysis, and the development of artificial intelligence-powered predictive algorithms. The work is in addition to Tempus’ current role as a provider of next-generation sequencing testing services to NYU Langone Health.
“Through the integration of advanced genomic technologies and data science, we are deepening our understanding of cancer’s complexity and pioneering transformative approaches for patient monitoring and treatment,” said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus. “Our research is focused on generating actionable insights through better understanding of cancer response, resistance, and trajectory that will not only refine and enhance current assays, but also drive the creation of innovative diagnostic tools and algorithms that can empower clinicians to deliver truly individualized care to their patients.”
The Tempus-NYU Langone collaboration will be carried out within routine clinical care at the Perlmutter Cancer Center, allowing researchers to study serial molecular profiling in real-world settings.
“This strategic collaboration will further our ability to analyze cutting-edge serial molecular profiling technology in the routine care of patients at the Perlmutter Cancer Center at NYU Langone Health,” said Shridar Ganesan, MD, PhD, Director of the Center for Molecular Oncology at Perlmutter Cancer Center. “This approach will enable us to better understand the biology of individual cancers, inform our ability to implement and develop targeted therapies, and assess response and emerging resistance.”
